Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Change in Cash (2016 - 2025)

Sonoma Pharmaceuticals has reported Change in Cash over the past 16 years, most recently at -$474000.0 for Q4 2025.

  • For Q4 2025, Change in Cash fell 140.93% year-over-year to -$474000.0; the TTM value through Dec 2025 reached -$2.7 million, down 194.52%, while the annual FY2025 figure was $2.2 million, 424.57% up from the prior year.
  • Change in Cash for Q4 2025 was -$474000.0 at Sonoma Pharmaceuticals, up from -$570000.0 in the prior quarter.
  • Over five years, Change in Cash peaked at $5.6 million in Q3 2021 and troughed at -$2.2 million in Q3 2022.
  • A 5-year average of -$149000.0 and a median of -$506500.0 in 2024 define the central range for Change in Cash.
  • On a YoY basis, Change in Cash climbed as much as 2516.02% in 2021 and fell as far as 3569.44% in 2021.
  • Year by year, Change in Cash stood at $137000.0 in 2021, then crashed by 623.36% to -$717000.0 in 2022, then surged by 137.52% to $269000.0 in 2023, then skyrocketed by 330.48% to $1.2 million in 2024, then crashed by 140.93% to -$474000.0 in 2025.
  • Business Quant data shows Change in Cash for SNOA at -$474000.0 in Q4 2025, -$570000.0 in Q3 2025, and -$1.8 million in Q2 2025.